Loading…
← CockpitCompetitor Analysis › AVBP ArriVent BioPharma, Inc.Open in the cockpit ↗

ArriVent BioPharma, Inc.AVBPCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Other

Biotech developing furmonertinib, an EGFR-targeted lung-cancer drug in-licensed from a Chinese partner, for global markets.

Momentum laggard 3
Mkt cap
$564M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$21.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.4%
Hurdle
n/a
no reverse DCF
Next earnings
112 days
10 Mar 2027
Close · USD$10.90
1D+2.0%
1W-19.3%
1M-42.2%
3M-62.6%
6M-60.0%
YTD-45.8%
1Y-47.3%
ATR %13.1%
Beta1.24
52w lowhigh69.6% off high

What ArriVent BioPharma does

Biotech developing furmonertinib, an EGFR-targeted lung-cancer drug in-licensed from a Chinese partner, for global markets.

Pre-revenue: it sells nothing and pays for trials from cash raised in its early-2024 listing and other share sales. Rights to furmonertinib outside Greater China come from Shanghai Allist, which sells it in China, so any US approval would bring milestone and royalty payments to Allist.

Products and services

  • Furmonertinib (EGFR-mutant NSCLC)
  • Pipeline in-licensed oncology assets

Where it sits in the supply chain

  • Oncology biopharma
  • In-licensed EGFR-inhibitor development
  • Global (ex-China) clinical/regulatory…

What could go right

  • US/global approval and launch of furmonertinib
  • New pipeline in-licensing

What could go wrong

  • Dependent on China originator data/IP
  • Binary late-stage trial and regulatory risk

Moat: narrow (IP / patents). Exclusive ex-China rights to a differentiated EGFR inhibitor already approved in China.

Headquarters: Newtown Square, Pennsylvania, US · Founded: 2021 · Employees: 77

Named competitors

ArriVent BioPharma at a glance

Size ArriVent BioPharma (AVBP) is a United States Health Care company (Pharmaceuticals: Other) with a market value of $564M, the 2583rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.90 on 18 Nov 2026.

Performance Over six months the shares fell 60.0%, against -22.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth The operating margin is -3,620.0% (peer median 12.2%).

Valuation It trades at 34.2× enterprise value to sales against a peer median of 2.9× (most expensive of 20).

Short interest Short interest is 11.8% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 79AVBP 40
Six months, rebased to 100: ArriVent BioPharma against the median of its 20 peers (local-currency closes).

ArriVent BioPharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.00M$0$0$0$0
Revenue growth—————
Gross profitn/a$0$0$0$0
EBITDA-$181M-$178M-$94.3M-$74.6M-$36.9M
Net income-$169M-$166M-$80.5M-$69.3M-$36.9M
Free cash flow-$153M-$161M-$70.2M-$55.8M-$43.6M
Capital expenditure$0$0$0$0$0
Total debt$256,000$14,000$176,000$317,000$139,000

Quarterly statements and history in the cockpit →

ArriVent BioPharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-40%-20%0%002644301507300261002412077500256260366931745030003960048828776032620460BOIPHN1707AVBP6-month return →1-month return →
Up and to the right = strong over both horizons. ArriVent BioPharma is the large dot.

ArriVent BioPharma competitors and peer comparison

Head to head with its named competitors (AVBP vs AZN.L vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
ArriVent BioPharma AVBP$564M-60%n/a-3,620%34.2×n/a
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%

How ArriVent BioPharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ArriVent BioPharma against its 20 peers (data as of 18 Nov 2026)
MeasureAVBPPeer medianRank in peer set
1-month return-42.2%-10.3%lowest of 21
6-month return-60.0%-22.1%lowest of 21
Distance from 52-week high-69.6%-44.4%lowest of 21
Operating margin-3,620.0%12.2%lowest of 21
EV / Sales34.2×2.9×most expensive of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%2.9×0.4%+1.0%
TSI 603262.SSChina$842M-46%+3%14%4.6×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%2.1×n/an/a
Boiron BOI.PAFrance$367M-31%-2%5%0.6×-0.8%-0.5%
PharmaNutra PHN.MIItaly$922M+2%+17%22%5.6×4.7%+18.5%
Daiken Biomedical 7780.TWTaiwan$342M-19%n/a18%3.0×-1.6%n/a
Grape King Bio 1707.TWTaiwan$342M-27%-5%19%1.0×-17.2%+2.3%

Questions

Who are ArriVent BioPharma's main competitors?
Named competitors: AstraZeneca (Tagrisso) (AZN.L), Johnson & Johnson (Rybrevant) (JNJ). The cockpit's measured peer set (industry) also includes Lanzhou Foci Pharmaceutical (002644.SZ), Hangzhou Minsheng Healthcare (301507.SZ), ABA Chemicals (300261.SZ), Hunan Hansen Pharmaceutical (002412.SZ), CK Life Sciences International (Holdings) (0775.HK), Shanxi Zhendong Pharmaceutical (300158.SZ).
Is ArriVent BioPharma expensive compared with its peers?
On ev / sales it trades at 34.2× against a peer median of 2.9×, most expensive of 20 in its peer set.
How has ArriVent BioPharma stock performed?
Over six months to 18 Nov 2026 the shares returned -60.0% against -22.1% for the median peer; over one year -47.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.